1. Raghu, G, Remy-Jardin, M, Myers, JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–e68.
Google Scholar | Crossref | Medline2. Wells, AU, Brown, KK, Flaherty, KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692.
Google Scholar | Crossref | Medline3. Cottin, V, Wollin, L, Fischer, A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 2019; 28: 180100.
Google Scholar | Crossref | Medline4. Lynch, DA, Sverzellati, N, Travis, WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med 2018; 6: 138–153.
Google Scholar | Crossref | Medline5. Raghu, G, Remy-Jardin, M, Ryerson, CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020; 202: e36–e69.
Google Scholar | Crossref | Medline6. Travis, WD, Costabel, U, Hansell, DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
Google Scholar | Crossref | Medline | ISI7. Furini, F, Carnevale, A, Casoni, GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med 2019; 6: 246.
Google Scholar | Crossref8. Ageely, G, Souza, C, De Boer, K, et al. The impact of multidisciplinary discussion (MDD) in the diagnosis and management of fibrotic interstitial lung diseases. Can Respir J 2020; 2020: 9026171.
Google Scholar | Medline9. Hatabu, H, Hunninghake, GM, Richeldi, L, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med 2020; 8: 726–737.
Google Scholar | Crossref | Medline10. Collard, HR, Ryerson, CJ, Corte, TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016; 194: 265–275.
Google Scholar | Crossref | Medline11. Salisbury, ML, Gu, T, Murray, S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 2019; 155: 699–711.
Google Scholar | Crossref | Medline12. Hoffmann-Vold, AM, Fretheim, H, Halse, AK, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 2019; 200: 1258–1266.
Google Scholar | Crossref | Medline13. Hoffmann-Vold, AM, Allanore, Y, Alves, M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021; 80: 219–227.
Google Scholar | Crossref | Medline14. Zamora-Legoff, JA, Krause, ML, Crowson, CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2017; 69: 542–549.
Google Scholar | Crossref | Medline15. Kawano-Dourado, L, Doyle, TJ, Bonfiglioli, K. Baseline characteristics and progression of a spectrum of interstitial lung abnormalities and disease in rheumatoid arthritis. Chest 2020; 158: 1546–1554.
Google Scholar | Crossref | Medline16. Zamora, AC, Hoskote, SS, Abascal-Bolado, B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med 2016; 118: 39–45.
Google Scholar | Crossref | Medline17. Kirkil, G, Lower, EE, Baughman, RP. Predictors of mortality in pulmonary sarcoidosis. Chest 2018; 153: 105–113.
Google Scholar | Crossref | Medline18. Khalil, N, Churg, A, Muller, N, et al. Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicol Pathol 2007; 35: 86–96.
Google Scholar | SAGE Journals | ISI19. Maher, TM, Corte, TJ, Fischer, A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8: 147–157.
Google Scholar | Crossref | Medline20. Kim, EJ, Elicker, BM, Maldonado, F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322–1328.
Google Scholar | Crossref | Medline | ISI21. Jacob, J, Hirani, N, van Moorsel, CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53: 1800869.
Google Scholar | Crossref | Medline22. Singh, N, Varghese, J, England, BR, et al. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis. Semin Arthritis Rheum 2019; 49: 358–365.
Google Scholar | Crossref | Medline23. Alberti, ML, Malet Ruiz, JM, Fernández, ME, et al. Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology 2020; 26: 3–9.
Google Scholar | Crossref | Medline24. Brown, KK, Martinez, FJ, Walsh, SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020; 55: 2000085.
Google Scholar | Crossref | Medline25. Lee, HY, Lee, KS, Jeong, YJ, et al. High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implications. Am J Roentgenol 2012; 199: 982–989.
Google Scholar | Crossref | Medline26. Walsh, SL, Sverzellati, N, Devaraj, A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22: 1672–1679.
Google Scholar | Crossref | Medline27. Lama, VN, Flaherty, KR, Toews, GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084–1090.
Google Scholar | Crossref | Medline | ISI28. Baron, M, Sutton, E, Hudson, M, et al. The relationship of dyspnoea to function and quality of life in systemic sclerosis. Ann Rheum Dis 2008; 67: 644–650.
Google Scholar | Crossref | Medline29. Khadawardi, H, Mura, M. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology 2017; 22: 501–507.
Google Scholar | Crossref | Medline30. Kreuter, M, Swigris, J, Pittrow, D, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res 2019; 20: 59.
Google Scholar | Crossref | Medline31. Kelly, CA, Saravanan, V, Nisar, M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics —a large multicenter UK study. Rheumatology 2014; 53: 1676–1682.
Google Scholar | Crossref | Medline | ISI32. Walsh, SL, Sverzellati, N, Devaraj, A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014; 69: 216–222.
Google Scholar | Crossref | Medline33. Jacob, J, Bartholmai, BJ, Rajagopalan, S, et al. Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis. Eur Radiol 2017; 27: 3635–3646.
Google Scholar | Crossref | Medline34. Doubková, M, Švancara, J, Svoboda, M, et al. EMPIRE Registry, Czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J 2018; 12: 1526–1535.
Google Scholar | Crossref | Medline35. Fu, Q, Wang, L, Li, L, et al. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol 2019; 38: 1109–1116.
Google Scholar | Crossref | Medline36. Solomon, JJ, Chung, JH, Cosgrove, GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47: 588–596.
Google Scholar | Crossref | Medline37. Goh, NS, Hoyles, RK, Denton, CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017; 69: 1670–1678.
Google Scholar | Crossref | Medline38. Gimenez, A, Storrer, K, Kuranishi, L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 2017; 73: 391–392.
Google Scholar | Crossref | Medline39. De Sadeleer, LJ, Hermans, F, De Dycker, E, et al. Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J 2020; 55: 1901983.
Google Scholar | Crossref | Medline40. Fernández Pérez, ER, Swigris, JJ, Forssen, AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644–1651.
Google Scholar | Crossref | Medline41. Assassi, S, Sharif, R, Lasky, RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
Google Scholar | Crossref | Medline42. Rojas-Serrano, J, Herrera-Bringas, D, Mejía, M, et al. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD). Clin Rheumatol 2015; 34: 1563–1569.
Google Scholar | Crossref | Medline43. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
Google Scholar | Crossref | Medline | ISI44. Lancaster, LH . Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2018; 13: 45.
Google Scholar | Crossref | Medline45. Swigris, JJ, Brown, KK, Abdulqawi, R, et al. Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180075.
Google Scholar | Crossref | Medline46. Hoffmann-Vold, AM, Maher, TM, Philpot, EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020; 2: E71–E83.
Google Scholar | Crossref47. Roofeh, D, Distler, O, Allanore, Y, et al. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord 2020; 5: 61–71.
Google Scholar | SAGE Journals48. Perelas, A, Silver, RM, Arrossi, AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 2020; 8: 304–320.
Google Scholar | Crossref |